Uremic Pruritus: Prevalence and Impact on Quality of Life and Depressive Symptoms in Hemodialysis Patients

Muhammad Zubair Satti 1, Danish Arshad 2, Hassan Javed 2, Ahmad Shahroz 2, Zeeshan Tahir 2, Mian Muhammad Hassan Ahmed 7, Arslan Kareem 3

1. Medicine, Rawalpindi Medical University and Allied Hospitals, Rawalpindi, PAK
2. Psychiatry, Rawalpindi Medical University and Allied Hospitals, Rawalpindi, PAK
3. Internal Medicine, Rawalpindi Medical University and Allied Hospitals, Rawalpindi, PAK

Corresponding author: Danish Arshad, danisharshad601@gmail.com

Abstract

Background

End-stage renal disease (ESRD) is a major public health problem with many associated symptoms. Uremic pruritus (UP) develops in 40% of patients on hemodialysis and has major effects on the patient’s life. It is also an independent risk factor for increased mortality, and its psychiatric implications remain poorly characterized in our local setup, where it tends to be underdiagnosed and undertreated.

Objectives and rationale

The study aims to report the prevalence of uremic pruritus in our study population and associate it with various patient parameters, which may define a subset of patients at high risk for this pruritus. We also assess the effects of uremic pruritus on the patient’s quality of life (by using the Dermatology Life Quality Index; DLQI) and depressive symptoms (by using the Public Health Questionnaire; PHQ-9).

Materials and methods

It was a descriptive, cross-sectional study conducted in the nephrology unit of the multi-organ failure (MOF) center of the Holy Family Hospital (HFH), Rawalpindi, Pakistan, from February 2019 to June 2019, during which 173 male patients on hemodialysis were selected. Informed consent was taken from patients and other skin-related causes of pruritis were excluded. Uremic pruritus was defined as pruritis lasting for at least three months after the onset of ESRD. The 5-D, PHQ-9, and DLQI questionnaires were used to assess pruritis, depressive symptoms, and quality of life, respectively. Their Cronbach’s Alpha values for 73 responses were 0.83, 0.81, and 0.71, respectively. The descriptive analysis was performed using SPSS v23.0 (IBM Corp, Armonk, NY, US). Spearman’s rank-order correlation, independent samples t-test, and one-way analysis of variance (ANOVA) were used to analyze study variables.

Results

The prevalence of uremic pruritus was 49.1%, with many patients having generalized itching. Unemployment and longer disease duration predisposed the patients towards uremic pruritus, as the mean 5-D score in this subset were greater (p<0.05 in the independent samples t-test). The results of one-way ANOVA were significant (p<0.05), indicating higher 5-D scores in worsening categories of depressive symptoms and quality of life. Spearman’s correlation matrix showed that 5-D, PHQ-9, and DLQI scores were strongly correlated with each other.

Conclusions

The prevalence of uremic pruritus among male hemodialysis patients is high, at 49.1%. It significantly contributes to depressive symptoms and a lower quality of life, which are associated with worse prognosis in hemodialysis patients. Thus, a clinician must keep in mind the psychiatric implications of uremic pruritus and treat it effectively to optimize the patient’s medical care.

Categories: Medical Education, Psychiatry, Nephrology

Keywords: uremic pruritus, end stage renal disease, depression, quality of life

Introduction

End-stage renal disease (ESRD), which mandates dialysis, is a burgeoning public health problem with an ever-increasing prevalence throughout the world. An estimated 200 million people are reported to suffer from chronic kidney disease (CKD) and many of these patients eventually progress to ESRD [1-3]. In recent times, many efforts have been made to improve the survival of hemodialysis patients with end-stage renal
disease. While hemodialysis has improved the survival rates, concerns regarding a reduction in quality of life (QoL) due to ESRD are worrisome and have been reported by numerous studies [4-5]. Thus, the need for an improvement in the quality of life in chronic hemodialysis patients with end-stage renal disease has been strongly emphasized.

The lower QoL in ESRD is because of many associated life-limiting symptoms such as pruritus. Pruritus associated with ESRD (called uremic pruritus) is an irritating sensation of the skin that causes a desire to scratch. The prevalence of uremic pruritus is reported to vary, affecting around one-third of these patients [6]. Moreover, unlike other symptoms of ESRD, dialysis only has the mild effect of reducing pruritus, and many patients undergoing hemodialysis complain of varying degree of pruritus [7-8]. The extent and severity of uremic pruritus vary between patients. In some patients, it is extensive and persistent while in others, it may be short-lived and localized. Severe uremic pruritus was found to be an independent risk factor of mortality in ESRD patients [9-10].

The exact pathogenesis of uremic pruritus remains unclear, but it is postulated to be multifactorial [11]. Histamine, parathormone, and electrolyte derangements (particularly of calcium and magnesium salts) have been implicated in pruritus and newer hypotheses focus on micro-inflammation and opioid-receptor malfunctions as possible causes of ESRD-associated pruritus [11-12]. There are a variety of therapeutic interventions that are useful in the treatment or reduction of the severity of uremic pruritus, such as correction of calcium and phosphorus levels, phototherapy, and acupuncture, with varying results [13].

Another CKD-associated condition is depressive symptoms with a high reported prevalence in this population [14]. It is associated with poor adherence to dialysis, medications, nutrition, poor quality of life, and higher mortality [14]. We hypothesize that one of many factors responsible for depressive symptoms may be uremic pruritus, as it lowers QoL, makes social interaction difficult, and leads to a continuous nagging sensation of itching along with disturbed sleep. All these possible effects of this pruritis have been linked to depressive symptoms in many studies [15]. However, we found no such study in our local set-up that considers the psychiatric implications of uremic pruritus.

Thus, chronic pruritis represents a serious public health concern that must be adequately addressed by clinicians. Despite the high prevalence and life-changing effects of pruritus in hemodialysis patients, the assessment of its effects on the lives of patients remains poorly characterized, especially in our local settings. Therefore, the goal of this study is to determine the prevalence and impact of uremic pruritus on the patient’s quality of life and to analyze whether it is associated with depressive symptoms in this population. We also assess various patient-related factors for their association with uremic pruritus. The results will help the local physicians to inquire and treat the pruritus in these patients so that their QoL can be improved. Furthermore, the results may also identify a subset of the dialysis population at high risk for uremic pruritus.

Materials And Methods

Study design

It was a descriptive, cross-sectional study conducted in the nephrology unit of the multi-organ failure (MOF) center of Holy Family Hospital (HFH), Rawalpindi, Pakistan, from February 2019 to June 2019. The study population included patients with ESRD on hemodialysis (for at least three months). Randomization was performed by systemic sampling in which patients coming for dialysis were numbered randomly, and each patient with an even number was selected for the study. The mini-mental state examination (MMSE) was used to evaluate the mental state of the patients, and those with a score of less than 19 were excluded from the study, as they may not be able to deliver reliable answers.

It was ensured that the itch reported by the patients was due to uremic pruritis and not because of related skin conditions, such as psoriasis, eczema, or dermatitis, by excluding them one by one. Uremic pruritus was defined as pruritus lasting for at least three months after the onset of ESRD. However, to ensure accurate recall, questions about the intensity and severity of the pruritus were asked, considering only the last two weeks according to the 5-D itch scale. During the study period, 173 male patients were interviewed at the bedside by trained investigators after obtaining informed consent. Only male patients were selected for the study because of their easy availability in the dialysis center of our hospital. Moreover, since males have a greater predisposition towards rapid progression to ESRD and earlier hemodialysis as compared to females, it is imperative to see the factors that affect their QoL [1]. Also, due to cultural norms in Pakistan, women tend to undergo peritoneal dialysis at home, which limits the accessibility to this subset of the population.

Questionnaires used

Multiple questionnaires were employed for the collection of data, including:

1) 5-D Itch Scale

To assess pruritus in the population, we used the 5-D itch scale, which inquires five dimensions related to
pruritus: duration, degree, direction, associated disability, and distribution of pruritus. The categories of the 5-D itch scale have been calibrated with the numeric rating scale (NRS) by a study that concludes that for the 5-D scale, scores of less than 9 mean no pruritus, 9-11 indicate mild, 12-17 indicate moderate, and 18-21 indicate severe pruritus [16].

2) Public Health Questionnaire-9

To assess depression, the Urdu version of the Public Health Questionnaire-9 (PHQ-9) was used, which is a nine-item scale with a scoring range of 0-27. Scores from 0-4 correspond to no depression, 5-9 show mild, 10-14 moderate, 15-19 to moderately severe, while scores above 20 are consistent with severe depression [17].

3) Dermatology Life Quality Index (DLQI)

The self-explanatory DLQI questionnaire was used to observe the effects of pruritus on a patient’s quality of life. Its reliability for the purpose is also well-established by many studies [18]. A score of 0-1 means there is no effect of pruritus on the patient’s life, 2-5 indicates small, 6-10 indicates moderate, 11-20 indicates large, and 21-30 means very large and severe limiting effects on the patient’s life due to the associated pruritus.

Cronbach’s alpha of the questionnaires

The inter-scale reliability of the questionnaire in our study population was assessed by calculating Cronbach’s alpha for the first 73 responses. It was 0.85 for the 5-D itch scale, 0.81 for PHQ-9, and 0.71 for DLQI, indicating the high reliability of these questionnaires in our study population.

Statistical analysis

A total of 173 male patients constituted our final sample for an alpha value of 0.05 and power of study at 80%. A descriptive analysis of the study variables was performed using SPSS v23.0 (IBM Corp, Armonk, NY, US). The normality of the data was checked by the Shapiro Wilk test. We assessed the population parameters that were significantly associated with the 5-D itch scale by the independent samples t-test (where means were compared) and Spearman’s rank-order correlation (where continuous variables were available). Then, we analyzed the difference in mean 5-D itch scores regarding different categories of PHQ-9 and DLQI questionnaires by one-way analysis of variance (ANOVA). Further, since the scores were non-normally distributed, continuous variables, a correlation matrix was drawn using Spearman’s rank-order correlation to observe the correlation between the 5-D, PHQ-9, and DLQI scores. A p-value of less than 0.05 was considered statistically significant.

Results

Population demographics and parameters are provided in Table 1. The table also shows the parameters that are significantly associated with the 5-D itch scale by appropriate tests of significance.

| Parameters                  | Test of significance with 5-D scores | p-values |
|-----------------------------|-------------------------------------|----------|
| Employment (n=173)          | Mean 5-D scores                     |          |
| Employed=116 (67.1%)        | 9.2±1.7                             |          |
| Independent samples t-test  |          | p=0.01                                      |
| Unemployed=57 (32.9%)       | 11.8±3.2                            |          |
| Session timing (n=173)      |          |                                            |
| Morning session=68 (39.3%)  | 10.7±2.5                            |          |
| Independent samples t-test  |          | p=0.53                                      |
| Evening session=105 (60.7%) | 11.1±2.9                            |          |
| Age=<39.4±4.3               | Spearman’s correlation r=0.14        | p=0.45                                           |
| Disease years=5.9±2.8       | Spearman’s correlation r=0.64        | p=0.002                                          |
| Hemodialysis years=2.1±1.2  | Spearman’s correlation r=0.12        | p=0.63                                           |

TABLE 1: Demographic details and their association with the 5-D score

Table 2 shows the details of pruritus in the population. The distribution of pruritus among patients was significant for generalized pruritus.
Parameter | Number of patients
---|---
Mean 5-D score of the population (n=173) | 10.9±2.3
Pruritus intensity (n=173)
No pruritus | 88 (50.9%)
Mild | 47 (27.2%)
Moderate | 29 (16.8%)
Severe | 9 (5.2%)
Distribution of pruritus among 85 pruritic patients
Arms | 13 (15.3%)
Legs | 12 (14.1%)
Face | 11 (12.9%)
Trunk and back | 15 (17.6%)
Generalized (2 or more areas) | 34 (40.0%)
Mean DLQI score (n=85) | 9.8±1.7
Mean PHQ-9 score (n=173) | 12.2±2.9
Chi-square test for the distribution of pruritis was significant at p=0.02

### TABLE 2: Details of pruritus in the population

| Parameter                  | PHQ-9 categories (n=173) | One-way ANOVA (p-value) |
|----------------------------|--------------------------|-------------------------|
|                            | No depression | Mild | Moderate | Moderately severe | Severe |    |
| Number of patients | 106 (61.3%) | 31 (17.9%) | 21 (12.1%) | 12 (6.9%) | 3 (1.7%) |    |
| 5-D itch score            | 8.1±1.8     | 10.7±2.5 | 13.1±3.7 | 17.6±4.8 | 19.5±5.8 | 0.001 |
| DLQI categories (n=85)    | No effect | Small | Moderate | Large | Extremely large | One-way ANOVA (p-value) |
| Number of patients | 16 (18.8%) | 20 (23.5%) | 29 (34.1%) | 14 (16.5%) | 6 (7.1%) |    |
| 5-D itch score            | 10.2±2.7 | 12.7±3.2 | 15.1±4.7 | 18.3±4.9 | 20.2±5.6 | 0.005 |

Table 3 shows the distribution of 5-D scores in different categories of PHQ-9 and DLQI scores. The scores increase in higher degrees of depressive symptoms or lifestyle limitation, which was statistically significant, as means scores had p<0.05 for both indices when calculated by one-way analysis of variance (one-way ANOVA).

### TABLE 3: 5-D scores in different categories of PHQ-9 and DLQI scores

| Parameter                  | PHQ-9 categories (n=173) | One-way ANOVA (p-value) |
|----------------------------|--------------------------|-------------------------|
|                            | No depression | Mild | Moderate | Moderately severe | Severe |    |
| Number of patients | 106 (61.3%) | 31 (17.9%) | 21 (12.1%) | 12 (6.9%) | 3 (1.7%) |    |
| 5-D itch score            | 8.1±1.8     | 10.7±2.5 | 13.1±3.7 | 17.6±4.8 | 19.5±5.8 | 0.001 |
| DLQI categories (n=85)    | No effect | Small | Moderate | Large | Extremely large | One-way ANOVA (p-value) |
| Number of patients | 16 (18.8%) | 20 (23.5%) | 29 (34.1%) | 14 (16.5%) | 6 (7.1%) |    |
| 5-D itch score            | 10.2±2.7 | 12.7±3.2 | 15.1±4.7 | 18.3±4.9 | 20.2±5.6 | 0.005 |

Table 4 shows the correlation matrix between the 5-D, PHQ-9, and DLQI scores drawn by using Spearman’s rank-order correlation.
Discussion

The results of our study provide important insights into the problem of uremic pruritus among male hemodialysis patients. We found a prevalence of 49.1% (85 out of 173) regarding uremic pruritus, where the majority of the patients had mild to moderate degrees of pruritus as classified by the 5-D itch scale. The prevalence is similar to what other studies reported and indicates the widespread occurrence of uremic pruritus in dialysis patients [19-21]. Many patients (40%) reported generalized pruritic itching involving their entire bodies, which were characteristically more severe on the face and back. Other patients (60%) said that itching was localized and the most common location was the trunk and back for localized itching sensation. Similar results were reported by another study, which also found that in many patients, uremic pruritus presented as generalized itching and discomfort among patients [7].

When we analyzed the association between uremic pruritus and patient parameters, we found some important associations with uremic pruritus. In our study, those males who were employed had significantly lower 5-D scores than unemployed males (p-value of t-test was 0.01). As employment keeps a person busy, the lower 5-D scores might relate to the psychological masking effect of a regular job, which may itself suppress the desire to itch. We also found that disease years had a moderate correlation with 5-D scores, at significant p-values. Since it is the decline in kidney function that contributes to uremic pruritus, more disease years will automatically translate to worsening kidney function and, hence, higher 5-D scores. The results are important and agree with another study conducted in Pakistan [22]. Our study indicates that age, hemodialysis years, and timing of dialysis session had no significant association with 5-D scores, which is in agreement with previous studies [20,23].

Next, we assess the distribution of 5-D scores in different categories of depression and lifestyle limitation. To have a good outlook of the effects of uremic pruritus, only the DLQI questionnaires of patients who had at least nine points in the 5-D scale were included in the analysis. This allowed us to measure QoL, particularly in association with uremic pruritus. No such modification was made for depressive symptoms because they have multifactorial causation. Our results indicate that depressive symptoms and lifestyle limitations are strongly correlated with 5-D scores and a significant ANOVA test concludes that higher degrees of PHQ-9 and DLQI have higher mean 5-D scores. A patient with higher 5-D scores, indicating worsening pruritus also suffers from a greater magnitude of depressive symptoms and lower QoL proportionately. This has an important clinical manifestation because a clinician must tend to treat pruritus in these patients by medical or non-medical measures instead of just waiting to see if it resolves with hemodialysis. Lower QoL and depressive symptoms have been linked to a lack of motivation, poor compliance with medical therapy, and higher mortality rates among hemodialysis patients [24]. Since both are significantly correlated with 5-D scores, a physician must always keep in mind the appearance of pruritus and its depressive effects in all patients of ESRD. These findings agree with many previous studies and underscore the grave consequences of untreated pruritus in hemodialysis patients [25-26].

Uremic pruritus generally remains undertreated in many dialysis patients and only routine antihistamines are prescribed, especially in developing countries [24,27]. By highlighting the importance of uremic pruritus in association with depressive symptoms and lower quality of life, our study calls for immediate and effective treatment of pruritus in hemodialysis patients so that their medical care is optimized and quality of life is improved.

Conclusions

The prevalence of uremic pruritus among male patients on hemodialysis was 49.1%. The pruritus was generalized in many patients, and unemployed males with longer disease years were more prone to suffer from this pruritus. The 5-D score was strongly correlated with depressive symptoms and lower QoL among subjects, indicating that uremic pruritus contributes to depression and lifestyle limitations. These findings mandate the need for the immediate and effective treatment of uremic pruritus among dialysis patients so
that their mortality is reduced and quality of life is enhanced.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Anderson S, Halter JB, Hazzard WR, et al.: Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol. 2009, 20:1199-1209. 10.1681 ASN.2008080860
2. Ojo A: Addressing the global burden of chronic kidney disease through clinical and translational research . Trans Am Clin Climatol Assoc. 2014, 125:229-245.
3. Senanayake S, Gunawardena N, Palihawadana P, Bandara P, Haniffa R, Karunarathna R, Kumara P: Symptom burden in chronic kidney disease: a population based cross sectional study . BMC Nephrol. 2017, 18:228. 10.1186/s12882-017-0638-y
4. Dgbrowska-Bender M, Dykowska G, Zuk W, Milewska M, Staniszewska A: The impact on quality of life of dialysis patients with renal insufficiency. Patient Prefer Adherence. 2018, 12:577-583. 10.2147/PAPA.S156556
5. Valderrabano F, Jofre R, Lopez-Gomez M: Quality of life in end-stage renal disease patients . Am J Kidney Dis. 2001, 38:445-464. 10.1053/ajkd.2001.26824
6. Manenti L, Tansienda P, Vaglio A: Uraemic pruritus: clinical characteristics, pathophysiology and treatment . Drugs. 2009, 69:251-263. 10.2165/00015555-200969050-00002
7. Mettang T, Kremer AE: Uremic pruritus. Kidney Int. 2015, 87:658-691. 10.1038/ki.2015.454
8. Razeghi E, Eskandari D, Ganji MR, Meyamie AP, Togha M, Khushayar P: Gabapentin and uremic pruritus in hemodialysis patients. Ben Fail. 2009, 51:85-90. 10.1080/08860200802395476
9. Weng CH, Hu CC, Yen TH, Hsu CW, Huang WH: Uremic pruritus is associated with two-year cardiovascular mortality in long term hemodialysis patients. Kidney Blood Press Res. 2018, 43:1000-1009. 10.1159/000490689
10. Wu H-Y, Huang J-W, Tsai W-C, et al.: Prognostic importance and determinants of uremic pruritus in patients receiving peritoneal dialysis: a prospective cohort study. PLoS One. 2018, 5,02053474.
11. Attia EAS, Hassan AA: Uremic pruritus pathogenesis, revisited. Arab J Nephrol Transplant. 2014, 7:91-96.
12. Mettang T, Kremer AE: Uremic pruritus. Kidney Int. 2015, 87:658-691. 10.1038/ki.2015.454
13. Simonsen E, Komenda P, Lerner B, et al.: Treatment of uremic pruritus: a systematic review . Am J Kidney Dis. 2017, 70:638-655. 10.1053/j.ajkd.2017.05.018
14. Geh ZS, Griva K: Anxiety and depression in patients with end-stage renal disease: Impact and management challenges - a narrative review. Int J Nephrol Renovasc Dis. 2018, 11:93-102. 10.2147/INRD.S126615
15. Khan A, Khan AH, Adnan AS, Sulaiman SAS, Mustaq S: Prevalence and predictors of depression among hemodialysis patients: a prospective follow-up study. BMC Public Health. 2019, 19:551. 10.1186/s12889-019-6796-z
16. Lai J-W, Chen H-C, Chou C-Y, et al.: Transformation of 5-D itch scale and numerical rating scale in chronic hemodialysis patients. BMC Nephrol. 2017, 18:56. 10.1186/s12882-017-0475-z
17. Grandner MA, Kripke DF, Youn IS, Youngstedt SD: Criterion validity of the Pittsburgh Sleep Quality Index: investigation in a non-clinical sample. Sleep Med B. 2006, 4:129-136. 10.1111/j.1479-8425.2006.00207.x
18. Lewis V, Finlay AY: 10 years experience of the Dermatology Life Quality Index (DLQI) . J Investig Dermatol Symp Proc. 2004, 9:169-180. 10.1111/j.1479-8425.2004.00911.x
19. Hu X, Sang Y, Yang M, Chen X, Tang W: Prevalence of chronic kidney disease-associated pruritus among adult dialysis patients. Medicine (Baltimore). 2018, 97:10653. 10.1097/md.0000000000010653
20. Ozcan N, Cinas FI, Ashin D, Mutt D: Uremic pruritus and associated factors in hemodialysis patients: a multi-center study. Kidney Res Clin Pract. 2018, 37:138-147. 10.23876/j.krcp.2018.37.2.138
21. Susel J, Batycka-Baran A, Reich A, Szepeotowski JC: Uraemic pruritus markedly affects the quality of life and depressive symptoms in haemodialysis patients with end-stage renal disease. Acta Derm Venereol. 2014, 94:276-281. 10.2340/00015555-1749
22. Rehman IU, Munib S, Ramadas A, Khan TM: Prevalence of chronic kidney disease-associated pruritus, and association with sleep quality among hemodialysis patients in Pakistan. PLoS One. 2018, 13:e0207758.
23. Adeyiowo O, Akinbobedewa A, Alii O, Ilatunji I, Ibuokun I: Prevalence, pattern and association of pruritus with quality of life in chronic kidney disease patients attending Kidney Care Centre, Ondo City, Southwest Nigeria. Ethi J Health Sci. 2016, 26:549. 10.4314/ejhs.v26i6.7
24. Shirazian S, Aina O, Park Y, et al.: Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges. Int J Nephrol Renovasc Dis. 2017, 10:113-26. 10.2147/INRD.S108065
25. Susel J, Batycka-Baran A, Reich A, Szepietowski JC: Uraemic pruritus markedly affects the quality of life and depressive symptoms in haemodialysis patients with end-stage renal disease. Acta Derm Venereol. 2014, 94:276-281. 10.2340/00015555-1749
26. Ibrahim MK, Elshahid AR, El Baz TZ, Elazab RM, Elhoseiny SA, Elsaie ML: Impact of uraemic pruritus on quality of life among end stage renal disease patients on dialysis. J Clin Diagnostic Res. 2016, 10:1-5. 10.7860/JCDR/2016/16273.7488

27. Combs SA, Teixeira JP, Germain MJ: Pruritus in kidney disease. Semin Nephrol. 2017, 35:383-391. 10.1016/j.semnephrol.2015.06.009